Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2024; 124(02): 152-162
DOI: 10.1055/a-2107-0815
Stroke, Systemic or Venous Thromboembolism

Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

Dongwon Yoon
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
,
Han Eol Jeong
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
,
Songhwa Choi
3   Medical Affairs, Pfizer Korea Ltd., Seoul, South Korea
,
Ju-Young Shin
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
4   Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
,
Soo-Mee Bang
5   Division of Hemato-Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints


Abstract

Background Venous thromboembolism (VTE) is associated with increased morbidity, mortality, and health care expenditure. However, the comprehensive utilization of anticoagulation therapy in patients with VTE, especially regarding active cancer, in real-world practice remains unclear.

Objective To describe the prescription, persistence, and patterns of anticoagulation therapy among patients with VTE stratified according to active cancer.

Methods Using Korean nationwide claims data, we identified an incident, treatment-naïve cohort of patients with VTE from 2013 to 2019 and classified them according to the presence/absence of active cancer. We explored the secular trends, treatment patterns (e.g., discontinuation, interruption, and switch), and persistence of anticoagulation therapy.

Results There were 48,504 and 7,255 patients without and with active cancer, respectively. Non-vitamin K antagonist oral anticoagulants (NOACs) were the most common anticoagulant in both groups (65.1 and 57.9%, respectively). The prescription of NOACs increased steeply over time, regardless of active cancer, whereas parenteral anticoagulants (PACs) plateaued and warfarin decreased sharply. A heterogeneous pattern was observed between the groups without and with active cancer (3-month persistence was 60.8, 62.9, 57.2, and 3.4%, respectively; 6-month persistence was 42.3, 33.5, 25.9, and 1.2% vs. 9.9%). Median durations of continuous anticoagulant therapy for warfarin, NOAC, and PAC were 183, 147, and 3 days in nonactive cancer patients, and 121, 117, and 44 days in active cancer patients.

Conclusion Our findings suggest that there were substantial differences in persistence, patterns, and patient characteristics of anticoagulant therapy based on index anticoagulant and active cancer.

Keywords

venous thromboembolism - anticoagulants - NOACs - treatment patterns - cancer

Supplementary Material



Publication History

Received: 20 December 2022

Accepted: 22 May 2023

Accepted Manuscript online:
07 June 2023

Article published online:
15 July 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Comment to this article:

Patterns and Persistence of Anticoagulant Use in the Treatment of Venous Thromboembolism: Insights from South KoreaThromb Haemost 2024; 124(02): 163-165
DOI: 10.1055/a-2131-7066

 

  • References

  • 1 Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388 (10063): 3060-3073
    CrossrefPubMedGoogle Scholar
  • 2 Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of venous thromboembolism in asian populations: a systematic review. Thromb Haemost 2017; 117 (12) 2243-2260
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Kim HY, Chang SA, Kim KH. et al; Venous Thromboembolism Research Group of Korean Society of Echocardiography. Epidemiology of venous thromboembolism and treatment pattern of oral anticoagulation in Korea, 2009-2016: a nationwide study based on the national health insurance service database. J Cardiovasc Imaging 2021; 29 (03) 265-278
    CrossrefPubMedGoogle Scholar
  • 4 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 5 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 6 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 7 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 8 Farge D, Bounameaux H, Brenner B. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 (10) e452-e466
    CrossrefPubMedGoogle Scholar
  • 9 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 10 Lyman GH, Bohlke K, Khorana AA. et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
    CrossrefPubMedGoogle Scholar
  • 11 Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119 (01) 60-68
    CrossrefPubMedGoogle Scholar
  • 12 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 13 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 14 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 15 Streiff MB, Holmstrom B, Angelini D. et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19 (10) 1181-1201
    PubMedGoogle Scholar
  • 16 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 17 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedGoogle Scholar
  • 18 Bang SM, Kang JH, Hong MH. et al. Treatment patterns and clinical outcomes in Korean cancer patients with venous thromboembolism: a retrospective cohort study. Clin Appl Thromb Hemost 2021; 27: 1076029620979575
    CrossrefPubMedGoogle Scholar
  • 19 Haas S, Ageno W, Weitz JI. et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost 2019; 17 (10) 1694-1706
    CrossrefPubMedGoogle Scholar
  • 20 Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017; 32 (05) 718-728
    CrossrefPubMedGoogle Scholar
  • 21 Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017. Res Pract Thromb Haemost 2019; 3 (04) 668-673
    CrossrefPubMedGoogle Scholar
  • 22 Sindet-Pedersen C, Pallisgaard JL, Staerk L. et al. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - a Danish nationwide cohort study. Sci Rep 2017; 7 (01) 3347
    CrossrefPubMedGoogle Scholar
  • 23 Lee CH, Fang CC, Tsai LM. et al. Changing treatment patterns in patients with venous thromboembolism in Taiwan. Circ J 2020; 84 (02) 283-293
    CrossrefPubMedGoogle Scholar
  • 24 Ghanima W, Schultze A, Donaldson R. et al. Oral anticoagulation therapy for venous thromboembolism in norway: time trends and treatment patterns. Clin Ther 2021; 43 (07) 1179.e3-1190.e3
    CrossrefPubMedGoogle Scholar
  • 25 Wilke T, Meinecke AK, Schaefer B, Buchwald S, Eriksson D, Müller S. Patient preferences for nonvitamin K antagonist oral anticoagulants in stroke prevention: a multicountry discrete choice experiment. Cardiol Res Pract 2019; 2019: 5719624
    CrossrefPubMedGoogle Scholar
  • 26 Kim SA, Lee JH, Lee JY. et al. Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study. Thromb Haemost 2022; 122 (12) 2011-2018
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 28 Hong J, Ahn SY, Lee YJ. et al; Korean Society of Hematology Thrombosis and Hemostasis Working Party. Updated recommendations for the treatment of venous thromboembolism. Blood Res 2021; 56 (01) 6-16
    CrossrefPubMedGoogle Scholar
  • 29 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedGoogle Scholar
  • 30 Delate T, Charlu M, Zhu S. et al. Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thromb Res 2020; 196: 367-370
    CrossrefPubMedGoogle Scholar
  • 31 Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med 2022; 175 (01) 20-28
    CrossrefPubMedGoogle Scholar
  • 32 Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 2019; 6 (01) e20-e28
    CrossrefPubMedGoogle Scholar
  • 33 Vora P, Soriano-Gabarró M, Suzart K, Persson Brobert G. Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies. Patient Prefer Adherence 2016; 10: 1657-1665
    CrossrefPubMedGoogle Scholar
  • 34 Haastrup SB, Hellfritzsch M, Rasmussen L, Pottegård A, Grove EL. Use of non-vitamin K antagonist oral anticoagulants 2008-2016: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol 2018; 123 (04) 452-463
    CrossrefPubMedGoogle Scholar
  • 35 Schaefer JK, Li M, Wu Z. et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost 2021; 19 (01) 212-220
    CrossrefPubMedGoogle Scholar
  • 36 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar